Detalhe da pesquisa
1.
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.
Clin Cancer Res
; 27(17): 4757-4767, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34140403